Expression and prognostic significance of the EGFR in solid tumors

[1]  N. Normanno,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? , 2006, Endocrine-related cancer.

[2]  R. Mariani-Costantini,et al.  ErbB‐receptors expression and survival in breast carcinoma: A 15‐year follow‐up study , 2006, Journal of cellular physiology.

[3]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[4]  G. Giaccone,et al.  Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies , 2005, International journal of cancer.

[5]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Normanno,et al.  Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. , 2005, Endocrine-related cancer.

[7]  S. Wiseman,et al.  Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival , 2005, Cancer.

[8]  N. Normanno,et al.  The ErbB receptors and their ligands in cancer: an overview. , 2005, Current drug targets.

[9]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[10]  A. Thor,et al.  Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[12]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[13]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[14]  H. Kölbl,et al.  Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing , 2004, International Journal of Gynecologic Cancer.

[15]  M. Kai,et al.  Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy , 2004, Cancer Research.

[16]  William J Gullick,et al.  Co‐expression of neuregulins 1, 2, 3 and 4 in human breast cancer , 2004, The Journal of pathology.

[17]  S. Hilsenbeck,et al.  Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. , 2004, Journal of the National Cancer Institute.

[18]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[19]  I. Bièche,et al.  Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.

[20]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[21]  O. Nanni,et al.  HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Fidler,et al.  Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. , 2003, Cancer research.

[23]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[24]  D. Rimm,et al.  Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors , 2003, Cancer.

[25]  H. Höfler,et al.  Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Normanno,et al.  Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. , 2003, Endocrine-related cancer.

[27]  A. Khorana,et al.  Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma , 2003, Cancer.

[28]  S. Tsutsui,et al.  Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. , 2003, American journal of surgery.

[29]  C. Schlotter,et al.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer , 2003, Breast Cancer Research.

[30]  J. Coll,et al.  Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines* , 2002, The Journal of Biological Chemistry.

[31]  J. Smyth,et al.  Neuregulin expression, function, and signaling in human ovarian cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  N. Normanno,et al.  Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. , 2002, International journal of oncology.

[33]  R. Chirino,et al.  Prognostic value of the quantitative measurement of the oncoprotein p185Her‐2/neu in a group of patients with breast cancer and positive node involvement , 2002, International journal of cancer.

[34]  C. Bucana,et al.  Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. , 2002, The American journal of pathology.

[35]  M. Volm,et al.  Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Kuwano,et al.  ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. , 2002, Cancer research.

[37]  J. C. Lee,et al.  Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. , 2002, European journal of cancer.

[38]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  G D Roodman,et al.  Biology of osteoclast activation in cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  T. Tzai,et al.  Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  H. Poulsen,et al.  The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  A. Ramaioli,et al.  Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Yasuhiro Ito,et al.  Expression of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Breast Carcinoma , 2001, Breast Cancer Research and Treatment.

[45]  N. Normanno,et al.  The role of EGF-related peptides in tumor growth. , 2001, Frontiers in bioscience : a journal and virtual library.

[46]  P. Ingrand,et al.  Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. , 2001, International journal of oncology.

[47]  N. Matsuura,et al.  Bimodal expression of heparin-binding EGF-like growth factor in colonic neoplasms. , 2001, Anticancer research.

[48]  A. Casamassimi,et al.  Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts , 2000, Oncogene.

[49]  F. Révillion,et al.  Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  O. Nanni,et al.  Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study , 2000, Breast Cancer Research and Treatment.

[51]  A. Casamassimi,et al.  EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  G. Millot,et al.  Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line , 1999, Oncogene.

[54]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[55]  N. Normanno,et al.  Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families. , 1999, International journal of oncology.

[56]  A. Casamassimi,et al.  EGF‐related peptides are involved in the proliferation and survival of MDA‐MB‐468 human breast carcinoma cells , 1999, International journal of cancer.

[57]  Kuala Lumpur Malaysia,et al.  Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.

[58]  I. Ellis,et al.  c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer , 1998, Oncogene.

[59]  R. Cardiff,et al.  Active signaling by Neu in transgenic mice , 1998, Oncogene.

[60]  S. Bull,et al.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  S. Hirohashi,et al.  A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases , 1998, Breast Cancer Research and Treatment.

[62]  I. Chong,et al.  Heparin-binding epidermal growth factor-like growth factor and transforming growth factor-alpha in human non-small cell lung cancers. , 1997, Journal of the Formosan Medical Association = Taiwan yi zhi.

[63]  W. Rath,et al.  Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. , 1997, Anticancer research.

[64]  S. Fox,et al.  The Epidermal Growth Factor Receptor in Breast Cancer , 1997, Journal of Mammary Gland Biology and Neoplasia.

[65]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  H. P. Fell,et al.  The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.

[67]  R. Cardiff,et al.  Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice , 1996, Molecular and cellular biology.

[68]  H. Friess,et al.  Co‐expression of heparin‐binding EGF‐like growth factor and related peptides in human gastric carcinoma , 1996, International journal of cancer.

[69]  N. Normanno,et al.  Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  D. Horsfall,et al.  Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer , 1996, International journal of cancer.

[71]  H. Friess,et al.  Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  A. Harris,et al.  Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas , 1995, Breast Cancer Research and Treatment.

[73]  U. Göhring,et al.  Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma. , 1995, Journal of the Society for Gynecologic Investigation.

[74]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[75]  Y. Matsuzawa,et al.  Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. , 1994, Gastroenterology.

[76]  G. Merlo,et al.  Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. , 1994, British Journal of Cancer.

[77]  R. Lupu,et al.  Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. , 1993, Cancer research.

[78]  N. Normanno,et al.  Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. , 1992, Cancer research.

[79]  K. Sugimachi,et al.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. , 1991, European journal of cancer.

[80]  D. Salomon,et al.  Transforming growth factor-alpha: an oncodevelopmental growth factor. , 1990, Cancer cells.

[81]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[82]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[83]  R. Derynck,et al.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. , 1986, Science.

[84]  U. Chetty,et al.  Prospective evaluation of prognostic factors in operable breast cancer , 2007 .

[85]  M. Campiglio,et al.  Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. , 2004, Journal of cellular physiology.

[86]  S. Tsutsui,et al.  Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer , 2004, Breast Cancer Research and Treatment.

[87]  L. Beex,et al.  Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study , 2004, Breast Cancer Research and Treatment.

[88]  M. Bolla,et al.  Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters , 2004, Breast Cancer Research and Treatment.

[89]  M. Ruge,et al.  Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[90]  C. Angeletti,et al.  Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.